Advagene Biopharma Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-68.29	-69.42	-92.11	-118.38	-92.69
Depreciation & Amortization	2.19	2.18	5.86	6.4	7.03
Other Amortization	-	-	6.14	5.2	0.7
Loss (Gain) From Sale of Investments	-	-	-	-	-0.05
Other Operating Activities	-0.16	-0.16	-0.08	0.12	0.16
Change in Accounts Receivable	-	0.01	-	-	3.99
Change in Accounts Payable	3.74	-1.91	0.5	0.07	-4.31
Change in Other Net Operating Assets	-0.8	-1.35	2	-2.77	-3.66
Operating Cash Flow	-63.33	-70.65	-77.7	-109.35	-67.18
Capital Expenditures	-2.31	-0.48	-	-0.21	-0.52
Sale (Purchase) of Intangibles	-	-	-	-10	-
Investment in Securities	70	-89.5	25	124.5	-79.5
Other Investing Activities	-	-0.01	1.5	-	-1.5
Investing Cash Flow	67.7	-89.99	26.5	114.29	-81.52
Long-Term Debt Repaid	-1.85	-1.74	-1.93	-1.83	-1.79
Net Debt Issued (Repaid)	-1.85	-1.74	-1.93	-1.83	-1.79
Issuance of Common Stock	-	150	100.31	0.57	42.93
Financing Cash Flow	-1.85	148.26	98.38	-1.26	41.14
Net Cash Flow	2.52	-12.38	47.18	3.67	-107.56
Free Cash Flow	-65.64	-71.12	-77.7	-109.56	-67.7
Free Cash Flow Per Share	-1.10	-1.30	-1.54	-2.22	-1.39
Cash Interest Paid	0.18	0.15	0.04	0.08	0.13
Cash Income Tax Paid	0.16	0.16	0.08	-0.12	-0.16
Levered Free Cash Flow	-41.78	-46.06	-43.87	-76.12	-55.71
Unlevered Free Cash Flow	-41.67	-45.96	-43.85	-76.07	-55.63
Change in Working Capital	2.93	-3.25	2.5	-2.7	17.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.